Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Samidorphan in dispersed granules
What ifWhat if coated samidorphan granules were dispersed throughout a single compressed tablet with olanzapine granules?
Claim language“a first tablet layer”
A water-soluble polyvinyl alcohol film surrounds the samidorphan granules before blending and compression. The film limits direct contact between the active ingredients in the dry tablet and dissolves as the tablet disintegrates.
1.1Sodium stearyl fumarate lubrication
What ifWhat if the samidorphan layer used sodium stearyl fumarate for lubrication?
Claim language“magnesium stearate”
Sodium stearyl fumarate is blended into the samidorphan granules after milling and before compression. It reduces friction between the compact and the die wall during tablet ejection.
1.2Lower diluent fraction
What ifWhat if the second diluent contributed 60 wt % based on the weight of the samidorphan layer?
Claim language“about 75-90 wt % of a second diluent”
A 100 mg samidorphan layer sets the reference mass, so the olanzapine layer contains 60 mg of microcrystalline cellulose. The cellulose provides compactability, and crospovidone promotes breakup of the olanzapine layer in water.
1.2Lubrication at the die wall
What ifWhat if the olanzapine blend contained no internal lubricant and the tablet press applied lubricant directly to the die wall?
Claim language“about 1.0 wt % magnesium stearate”
A metered dusting nozzle applies sodium stearyl fumarate to the die wall before filling. The surface deposit reduces friction during ejection while the bulk olanzapine blend contains the drug, diluent, and disintegrant.
1.3Capillary electrophoresis impurity assay
What ifWhat if the assay used capillary electrophoresis with ultraviolet detection to quantify olanzapine degradation products?
Claim language“using HPLC”
A fused-silica capillary containing an aqueous buffer and an anionic surfactant separates tablet extract components under an applied voltage. Calibration solutions containing the degradation products relate their ultraviolet peak areas to the amounts present in the tablet extract.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Bilayer tablets for instrument qualification
An analytical laboratory uses bilayer tablets as control articles for dissolution instruments. One layer contains 10 mg of samidorphan and the other contains a fixed dose of olanzapine, with a diluent and magnesium stearate in each layer. The laboratory assigns a reference release profile for each active from replicate tests on the control lot. During instrument checks, liquid chromatography measures both actives in timed samples for comparison with their reference profiles.
Component substitution
Sodium stearyl fumarate as lubricant
Sodium stearyl fumarate replaces magnesium stearate in both layers. The samidorphan layer and the olanzapine layer each contain their own diluent blend. A separate blending step adds the lubricant to each blend before the two blends enter their respective press feeders. Ejection force and layer adhesion measurements guide the lubricant concentration in each blend.
Parameter or scale variation
Dissolution sampling during early release
A paddle vessel holds 900 mL of acetate buffer at pH 4.5 and 37 °C, and the paddle turns at 50 rpm. A sinker holds the bilayer tablet at the bottom of the vessel. A sampling probe withdraws aliquots at 2, 5, 10, 15 and 30 minutes, and fresh buffer replaces each aliquot. Liquid chromatography quantifies both actives, and the release calculation accounts for the drug removed in earlier samples.
Combination with existing systems
Bilayer tablets in cold formed blisters
A blister packaging line places one bilayer tablet in each cavity of a cold formed aluminum laminate. A heat sealing station bonds aluminum lidding around each cavity to form an individual moisture barrier. Packaged stability samples provide tablets for liquid chromatography measurement of olanzapine degradation and for dissolution testing of both actives.
Automated or data-driven variant
Sensor feedback for layer fill
A rotary bilayer press uses separate feed frames for the samidorphan and olanzapine blends. A force sensor records first-layer tamping force, and an automated sampling station weighs finished tablets. A calibration built from first-layer samples links tamping force to first-layer mass at a fixed punch setting, and the controller subtracts the estimated first-layer mass from finished tablet mass to estimate second-layer mass. The controller adjusts the two fill depths using their respective mass estimates.
Vision inspection of tablet edges
A station downstream of the press rolls each tablet on driven rollers while a camera images its edge under low-angle lighting. Image processing measures the position of the interface and locates visible cracks and chips around the circumference. The controller compares those measurements with configured limits and diverts tablets that fall outside them.
Specific version of a part
Lactose and cellulose diluent blend
The samidorphan layer contains 60 wt % lactose monohydrate, 22 wt % microcrystalline cellulose, and 1.75 wt % magnesium stearate, each based on the weight of that layer. Lactose supplies soluble bulk, and microcrystalline cellulose supports compaction.
Mannitol based olanzapine layer
The olanzapine layer contains 10 mg of olanzapine and 80 mg of spray-dried mannitol when the samidorphan layer weighs 100 mg. The olanzapine blend contains 1.0 wt % magnesium stearate based on its own weight, added during final blending before compression.
Reversed phase impurity assay
A reversed-phase HPLC assay uses an octadecylsilane column, an aqueous buffer and acetonitrile gradient, and ultraviolet detection. The assay quantifies resolved olanzapine degradation peaks against calibrated reference solutions and reports their combined weight percentage after six months of storage.
Desiccant below a perforated tray
A perforated tray holds the tablets above a compartment containing 250 g of silica gel inside a closed container. Air circulates between the tray and the desiccant while the container remains in a chamber at 25 °C and 60% relative humidity for six months.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1a first tablet layer comprising: 10 mg samidorphan or a pharmaceutically acceptable salt of samidorphan in an amount to deliver 10 mg samidorphan; about 75-90 wt % of a first diluent selected from the group consisting of lactose or a hydrate thereof, microcrystalline cellulose, mannitol, sorbitol, xylitol, dicalcium phosphate, starch and combinations thereof; based on the weight of the first tablet layer; and about 1.5 to about 2 wt % of magnesium stearate;
Composition I also contains microcrystalline cellulose at about 56% wt/wt of the composition; croscarmellose sodium at about 6% wt/wt of the composition; magnesium stearate at about 0.25% wt/wt of the composition; and anhydrous lactose at about 37% wt/wt of the composition.
B · US 8,513,240 B2 · ¶ 29
1.2a second tablet layer comprising: a dose of olanzapine selected from the group consisting of 5 mg, 10 mg, 15 mg and 20 mg of the olanzapine; about 75-90 wt % of a second diluent selected from the group consisting of lactose or a hydrate thereof, microcrystalline cellulose, mannitol, sorbitol, xylitol, dicalcium phosphate, starch and combinations thereof; based on the weight of the first tablet layer; and about 1.0 wt % magnesium stearate;
Composition I also contains microcrystalline cellulose at about 56% wt/wt of the composition; croscarmellose sodium at about 6% wt/wt of the composition; magnesium stearate at about 0.25% wt/wt of the composition; and anhydrous lactose at about 37% wt/wt of the composition.
B · US 8,513,240 B2 · ¶ 29
1.3wherein less than 0.5 wt % impurities from olanzapine degradation are detected, using HPLC, after the tablet is stored for 6 months in a closed container containing 250 g silica gel desiccant at 25 °C and 60% relative humidity.
In one embodiment, Compositions I and II degrade less than about 4% over a period of greater than 1 month at temperatures at or greater than about 25° C. and a relative humidity at or greater than about 60%.
B · US 8,513,240 B2 · ¶ 63
An empty cell means only that no passage was reproduced there.
Statements in these documents
No. 6,645,523 ('523 patent) discloses that coloration problem, i.e. the pink hue, in paroxetine tablets, involves the formation of a coloring impurity identified as compound A which is a dimer formed from paroxetine free base in an aqueous alkaline environment.
A · US 2006/0216345 A1 · ¶ 4
Thus, the invention discloses a solid paroxetine composition that resists the formation of a colour hue and to processes for making the same with the aid of water, by controlling the pH of the composition to 6.5 or less.
A · US 2006/0216345 A1 · ¶ 4
Tanaproget, 5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile, is a progesterone receptor modulator and is effective in contraception, hormone replacement therapy, and treating carcinomas and adenocarcinomas, dysfunctional bleeding, uterine leiomyomata, endometriosis, and polycystic ovary syndrome.
B · US 8,513,240 B2 · ¶ 6
What is needed in the art are compositions containing tanaproget for administration to a mammalian subject.
B · US 8,513,240 B2 · ¶ 7
Cite aspatent.fyi, US 2026/0355214 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355214/, SHA-256 2542ced0078dd42a8eb15b84ef0e159123392b0253c2e4c712fa7d79db44cad3